Equibles does not estimate personal net worth.
Earlier roles on record: CEO and Board Member at Travere Therapeutics, Inc. (TVTX) until December 1, 2026. Travere Therapeutics, Inc. reported in an 8-K filed September 21, 2026 that Eric Dube resigned as member of the Board of Directors, effective December 1, 2026. Travere Therapeutics, Inc. reported in an 8-K filed September 21, 2026 that Eric Dube resigned as President and Chief Executive Officer, effective December 1, 2026. Travere Therapeutics, Inc. reported in an 8-K filed May 16, 2025 that Eric Dube was appointed Director, effective May 15, 2025. Equibles holds 5 filed executive changes naming Eric Dube; each is listed under recent activity with its source filing. The proxy statement of Travere Therapeutics, Inc. reports total compensation of $8,457,151 for Eric Dube in fiscal 2025, including a base salary of $854,250. Disclosed compensation is on record for 7 fiscal years. Eric Dube has spoken on 26 earnings calls and 4 other investor events across 1 company, most recently for Travere Therapeutics, Inc. on August 4, 2026. The companies whose calls Eric Dube spoke on are classified in the Healthcare sector.
“who will step down from his position as the Company's President and Chief Executive Officer and as a member of the Board of Directors of the Company effective as of December 1, 2026”
“Eric Dube, Ph.D., mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position as the Company's President and Chief Executive Officer and as a member of the Board of Directors of the Company effective as of December 1, 2026”
“Our performance demonstrates the strength of the company we are building and the disciplined execution of our teams.”
“So for investors who may be a little bit newer to the story, could you provide a brief background on Trevere and overview of your program sure so Trevere Therapeutics is a rare disease company based in San Diego and we have a commercial footprint focused on rare kidney disease particularly with Phil Spari which is now…”
“So Trevere Therapeutics is a commercial and development stage biotech company focused on innovation in rare diseases. You can find more information, including our forward-looking statements, on our website.”
“And you can go on to our website for a pretty extensive corporate deck with background information as well as forward-looking statements. Trevere Therapeutics is a commercial stage rare disease company.”
“This has been a tremendous start to the year for Trevere. We've made significant progress across our three strategic priorities. We achieved the first FDA approval in FSGS.”
2019-01-01–2026-12-01
Start not stated–2026-12-01
Biotechnology · Healthcare
CEO, Board Member
2019-01-01–2026-12-01
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $854,250 | $8,457,151 |
| 2024 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $822,000 | $5,204,877 |
| 2023 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $795,834 | $7,574,959 |
| 2022 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $746,667 | $5,753,490 |
| 2021 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $708,021 | $5,739,010 |
| 2020 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $660,938 | $5,447,879 |
| 2019 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $618,188 | $9,679,319 |
